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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effects of balloon dilatation of the Eustachian tube in adults with obstructive Eustachian tube dysfunction.
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B A C K G R O U N D
Description of the condition
The Eustachian tube is a narrow tube approximately 35 mm long in
adults, which extends from the back of the nose (nasopharynx) to
the middle ear. The two-thirds closest to the nasopharyngeal open-
ing is made from cartilage and other soG tissue, whilst the third
closest to the middle ear is a bony tube within the temporal bone.
The Eustachian tube performs three primary functions: 1) pressure
equalisation and ventilation of the middle ear; 2) mucociliary clear-
ance of secretions from the middle ear; and 3) protection of the
middle ear from sounds and from pathogens or secretions from the
nasopharynx (Bluestone 2005; Sade 1997). To fulfil these functions
the Eustachian tube is normally closed, but it opens momentarily
either actively during swallowing or passively due to a pressure gra-
dient (Alper 2012; Poe 2000).
The most important function of the Eustachian tube is mainte-
nance of an ambient middle ear air pressure to facilitate sound
transmission from the ear drum to the middle ear. Two processes
act on the middle ear gas pressure. The first is gas exchange across
the middle ear cleG cell lining, which tends to create a negative
pressure (Adil 2014; Pau 2009); the second process is Eustachian
tube opening, which permits intermittent equalisation of middle
ear pressure with atmospheric pressure via the nose.
Eustachian tube dysfunction is usually defined by symptoms and
signs of pressure dysregulation in the middle ear, resulting in symp-
toms of ear fullness, popping and crackling sounds, ear discom-
fort, muffled hearing and tinnitus (McCoul 2012b; Schilder 2015).
It can also be a mechanism for middle ear disease and is associat-
ed with tympanic membrane retraction, otitis media with effusion
('glue ear') and chronic otitis media (Bluestone 2005). Eustachian
tube dysfunction and these related middle ear conditions account
for over two million adult hospital visits per annum in the USA (Vila
2017), and prevalence in the UK was previously reported to be 0.9%
(Browning 1992).
An expert consensus group has agreed on definitions for acute
and chronic Eustachian tube dysfunction, with acute dysfunction
relates to transient symptoms and signs for up to three months,
and chronic dysfunction relates to symptoms and signs for more
than three months (Schilder 2015). The consensus group further
categorised Eustachian tube dysfunction into dilatory, baro-chal-
lenge-induced and patulous dysfunction. The term 'obstructive'
Eustachian tube dysfunction is used widely in clinical practice and
in the medical literature, and refers to dilatory Eustachian tube dys-
function, which indicates a problem with the ventilatory function
of the Eustachian tube in conditions of normal atmospheric pres-
sure. Dilatory dysfunction may be due to functional obstruction, dy-
namic dysfunction (e.g. muscular failure) or anatomic obstruction
(Bluestone 2005; Doyle 2013; Schilder 2015).
Patient-reported outcome measures (PROMs) for Eustachian tube
dysfunction include the Eustachian Tube Dysfunction Question-
naire (ETDQ-7) (McCoul 2012b) and the Eustachian Tube Score (ETS)
and its extension (ETS-7), which combine subjective patient-re-
ported symptom scores with clinical findings. A retracted tym-
panic membrane on examination of the ear, or type B or C tym-
panogram trace indicating abnormal middle ear function (Jerg-
er 1972), are commonly used as 'indicators' of Eustachian tube
dysfunction both in clinical practice and research studies. More
complex tests of Eustachian tube function are primarily used in
research, the most common of these being tubomanometry and
sonotubometry, which respectively measure pressure and sound
transmitted down the Eustachian tube as it opens during swallow-
ing (Smith 2015).
The most significant issue relating to research in this field is the lack
of a gold-standard reference test against which to measure the ac-
curacy of proposed diagnostic tests for Eustachian tube function.
In clinical practice, most diagnoses are made based on patient-re-
ported symptoms combined with otoscopic and tympanometric
findings. However, these do not correlate well with objective mea-
sures of Eustachian tube opening, that is sonotubometry and tubo-
manometry (Smith 2018). PROMs therefore have poor diagnostic
value and are perhaps best used only when monitoring symptoms
or response to treatment. Whilst an agreed approach to the diag-
nosis of Eustachian tube dysfunction is still lacking, a combination
of objective measures of Eustachian tube opening (tympanometry,
sonotubometry and tubomanometry) and clinical opinion is cur-
rently advised (Smith 2018).
Symptoms attributed to chronic Eustachian tube dysfunction are
often treated conservatively. Interventions aiming to improve the
underlying Eustachian tube dysfunction, or to provide an alterna-
tive method of middle ear ventilation, include non-surgical and sur-
gical approaches. Non-surgical interventions typically used as first-
line treatments include pharmacological treatments such as nasal
steroids and decongestants, and manual autoinflation devices that
aim to equalise middle ear pressure (Perera 2013). Surgical inter-
ventions may require general anaesthesia and include myringo-
tomy with ventilation tube (grommet) insertion, laser Eustachian
tuboplasty and Eustachian tube balloon dilatation. A 2014 system-
atic review found limited evidence and could not draw conclusions
regarding the effectiveness of any of the interventions for adult Eu-
stachian tube dysfunction (Llewellyn 2014).
Description of the intervention
Balloon Eustachian tuboplasty (BET) is a method of dilating the
cartilaginous Eustachian tube using a catheter-mounted balloon. A
number of BET devices are available, with variable diameters and
length. BET is typically performed under a general anaesthetic and
transnasally, under endoscopic guidance using an angled rigid en-
doscope. The balloon catheter is inserted into the nasopharyngeal
opening of the Eustachian tube using an angled introducer and
gently advanced until the balloon is fully inserted at approximate-
ly 20 mm, where there is a defined stop point that prevents the
balloon being over-inserted into the bony Eustachian tube. This is
where an aberrant course or dehiscent carotid might be present
and at risk during the procedure. Once positioning is confirmed, a
manually operated syringe allows inflation of the balloon to a pres-
sure of around 10 atmospheres. At this pressure, the balloon adopts
a pre-defined size and is relatively rigid. The balloon is leG in situ for
one to two minutes before being deflated and removed. This pro-
cedure takes between three and five minutes per Eustachian tube.
Some groups have used BET in combination with another surgical
procedure including both sinonasal and otological surgery (Cata-
lano 2012). Other co-interventions, such as septoplasty (Catalano
2012), can be used to improve access to the nasopharynx and Eu-
stachian tube. It is unclear what effect, if any, these interventions
may have on Eustachian tube dysfunction or associated symptoms.
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Adverse effects of BET have been reported in the literature, the ma-
jority of which occur at the time of surgery and are mild and self-lim-
iting, such as minor bleeding from the site of tuboplasty or emphy-
sema that resolves within a few days (Poe 2011b; Schroder 2015).
Other early adverse effects are a temporary increase in rhinitic
symptoms (Gürtler 2015) and tinnitus (Schroder 2015). Complica-
tions requiring a return to theatre for a revision procedure have
been reported (McCoul 2012c), as have early adverse effects such
as a temporary increase in rhinitic symptoms. Late complications
have not been widely reported (Huisman 2018; Randrup 2015). We
have not found reports of carotid rupture.
How the intervention might work
The balloon dilatation technique has been employed for many
years in cardiology and vascular surgery as a method of dilating
narrowed vessels. The technique was modified and adopted by ENT
surgeons for balloon sinuplasty in 2005, before being applied to the
Eustachian tube in 2009. Although BET has been extensively used
clinically in some countries, the inaccessibility of the Eustachian
tube has limited investigation into the mechanism of the proce-
dure. Little is known about the immediate effect of the balloon on
soG tissues and any subsequent healing process.
The Eustachian tube opening is reported to appear widened after
dilatation (Poe 2011b). In addition, an increase in the cross-section-
al area of the Eustachian tube after dilatation has been reported on
computed tomography (CT) imaging (Poe 2011a).
Cadaver studies have suggested that the mucosal lining of the Eu-
stachian tube is crushed and the cartilage cracked during BET (Mc-
Coul 2012a; Ockermann 2010; Poe 2011a). A single in vivo histolog-
ical study reported that patients with Eustachian tube dysfunction
had an abnormal, inflamed Eustachian tube lining prior to surgery,
and biopsies taken immediately after BET demonstrated a diffuse
crush injury and shearing of the superficial tissues (Kivekas 2015). In
three cases, additional biopsies were obtained 5 to 12 weeks post-
operatively, which showed restoration of largely uniformly healthy
cells lining the Eustachian tube.
It has therefore been hypothesised that BET crushes unhealthy mu-
cosa, promoting replacement with normal tissue. This correlates
with visual findings in patients from uncontrolled series where sur-
face inflammation was scored before BET and after a follow-up pe-
riod (Poe 2011b; Silvola 2014). It is postulated that a wider opening
and healthier cell lining after BET treatment might return the pre-
viously dysfunctional Eustachian tube to normal function.
Why it is important to do this review
Initial published data on BET have largely been limited to case se-
ries (Huisman 2018; Miller 2013; Randrup 2015), prohibiting firm
conclusions regarding efficacy. Nevertheless, BET is already be-
ing adopted into clinical practice within many European coun-
tries, North America and Asia. In 2011, the UK National Institute
for Health and Care Excellence (NICE) issued guidance on BET, con-
cluding that evidence on procedure efficacy and safety was inad-
equate in quantity and quality (NICE 2011), and suggesting at the
time that BET should only be performed in the research setting.
Since this guidance further trials have been published including
randomised controlled trials (Meyer 2018; Poe 2017).
O B J E C T I V E S
To evaluate the effects of balloon dilatation of the Eustachian tube
in adults with obstructive Eustachian tube dysfunction.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include studies with the following design characteristics:
• Randomised controlled trials.
We will include trials randomised both 'by patient' and 'by ear' pro-
viding, in the latter case, that the effects of treatment (both BET and
the comparator) are measured using ear-specific outcome mea-
sures (e.g. tympanometry).
The Unit of analysis issues section provides further details on how
data will be analysed if both split-person and between-person stud-
ies are included.
Types of participants
Individuals aged 18 years or older with chronic (more than three
months duration) obstructive Eustachian tube dysfunction, as de-
fined by the diagnostic criteria used by the trial investigators.
We will not exclude patients who have had previous medical or sur-
gical treatment of Eustachian tube dysfunction. If paediatric cases
have been included in a study, we will extract the adult data if par-
ticipants were stratified by age prior to randomisation. If not, we
will accept a level of 'contamination' with paediatric cases, as long
as the adults make up more than 75% of the population.
We will exclude studies that include patients with:
• nasopharyngeal malignancy or excised malignancy obstructing
the Eustachian tube;
• past radiation therapy to the head and neck;
• cleG palate or repaired cleG palate;
• craniofacial syndrome including Down syndrome;
• ciliary dysmotility syndrome.
Types of interventions
Intervention
Dilatation of the Eustachian tube by the inflation of a balloon of any
size or pressure, by any surgical approach.
Co-interventions
BET may be performed at the same time as an additional otologi-
cal or nasal procedure. If both intervention and comparator groups
have been treated in the same way in this regard, we will include the
study. Examples may include adenoidectomy, myringotomy and
ventilation tube insertion. A study would also be included if the co-
intervention has no effect on Eustachian tube function; for exam-
ple, suction clearance of the external ear for examination purposes.
Comparisons
The main comparisons will be:
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• BET versus no treatment;
• BET versus non-surgical treatment (medical and/or autoinfla-
tion devices).
Other comparison pairs will include:
• BET versus grommet (ventilation tube) insertion;
• BET versus laser tuboplasty.
Types of outcome measures
We will analyse the following outcomes in the review, but they will
not be used as a basis for including or excluding studies.
We will extract data on outcomes according to the following time
points: 0 to < 3 months, 3 to < 12 months, 12 to < 24 months, 2 to
5 years.
Primary outcomes
• Obstructive Eustachian tube dysfunction symptoms - severity
(patient-reported). This must be formally assessed using a val-
idated questionnaire or scoring method (e.g. ETDQ-7; McCoul
2012b).
• Eustachian tube function measured by an objective or semi-ob-
jective test (e.g. sonotubometry, tubomanometry) (Smith 2015).
• Serious adverse events.
Secondary outcomes
• Hearing: changes in hearing thresholds from pre-intervention
levels, measured in dB HL, using any conventional averaging
method.
• Tympanic membrane abnormalities (e.g. presence of retraction
pockets or perforations).
• Quality of life, as measured using a validated scoring system
(e.g. EQ-5D, SF-36).
• Need for revision treatment.
• Other adverse events: including acute otitis media, or stenosed
or patulous Eustachian tube.
Search methods for identification of studies
The Cochrane ENT Information Specialist will conduct systemat-
ic searches for randomised controlled trials and controlled clinical
trials. There will be no language, publication year or publication
status restrictions. We may contact original authors for clarifica-
tion and further data if trial reports are unclear and we will arrange
translations of papers where necessary.
Electronic searches
Published, unpublished and ongoing studies will be identified by
searching the following databases from their inception:
• the Cochrane ENT Trials Register (search via the Cochrane Reg-
ister of Studies to date);
• the Cochrane Central Register of Controlled Trials (CENTRAL)
(search via the Cochrane Register of Studies to date);
• Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
(1946 to date);
• Ovid Embase (1974 to date);
• LILACS (Latin American and Caribbean Health Science Informa-
tion database; 1982 to date);
• Web of Knowledge, Web of Science (1945 to date);
• CNKI (searched via Google Scholar to date);
• ClinicalTrials.gov, www.clinicaltrials.gov (search via the
Cochrane Register of Studies to date);
• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (search to date).
The subject strategies for databases will be modelled on the search
strategy designed for CENTRAL (Appendix 1). Where appropriate,
these will be combined with subject strategy adaptations of the
highly sensitive search strategy designed by Cochrane for identi-
fying randomised controlled trials and controlled clinical trials (as
described in the Cochrane Handbook for Systematic Reviews of In-
terventions Version 5.1.0, Box 6.4.b. (Handbook 2011)).
Searching other resources
We will scan the reference lists of identified publications for addi-
tional trials and contact trial authors if necessary. In addition, the
Information Specialist will search Ovid MEDLINE, the Cochrane Li-
brary and Google to retrieve existing systematic reviews relevant to
this systematic review, so that we can scan their reference lists for
additional trials. The Information Specialist will also run non-sys-
tematic searches of Google Scholar to retrieve grey literature and
other sources of potential trials.
We will not perform a separate search for adverse effects of balloon
dilatation of the Eustachian tube for obstructive Eustachian tube
dysfunction in adults. We will consider adverse effects described in
the included studies only.
Data collection and analysis
Selection of studies
Two authors (AP and MS) will independently screen the titles and
abstracts of every record identified in the search and indicate which
reports should be retrieved. If there is insufficient information in
the title and abstract to make such decisions, we will retrieve the
full text. Two review authors (AP and MS) will independently read
the full reports and determine whether these studies meet the in-
clusion criteria. We will resolve disagreements via discussion, or
with a third review author as necessary. If resolving the disagree-
ment is not possible, we will contact the authors for clarification.
We will include an adapted PRISMA (Preferred Reporting Items for
Systematic reviews and Meta-Analyses) flow chart of study selec-
tion (Liberati 2009).
Data extraction and management
For each included study, two review authors (AP and MS) will inde-
pendently extract and record the following data using a piloted da-
ta collection form:
• Source: study, report and author ID, citation and contact details.
• Methods: study design, unit of randomisation, unit of analysis,
total study duration, setting and follow-up.
• Participants: total number, setting, diagnostic criteria, age, sex,
country, prior treatment, co-morbidity, socio-demographics;
data on different presentations of Eustachian tube dysfunction
(including presence of OME, tympanic membrane retraction,
tympanic membrane perforation and cholesteatoma). We will
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also extract symptoms of Eustachian tube dysfunction without
any abnormal signs.
• Interventions: total number of intervention groups, details of
specific intervention (i.e. balloon size, inflation pressure and de-
vice design), prior medical or surgical interventions, any co-in-
terventions. A recent systematic review found that no interven-
tion has been demonstrated to be an effective treatment for
Eustachian tube dysfunction (Llewellyn 2014), so we will group
comparators in our analysis into medical and surgical treat-
ments.
• Outcomes: outcome measures and time points (i) collected and
(ii) reported, outcome definition, unit of measurement. We will
categorise adverse events as early if occurring within 24 hours
of the intervention or the start of medical treatment, or late if
occurring more than 24 hours after. We will grade adverse events
by severity according to the Clavien-Dindo system (Dindo 2004).
• Results: sample size, missing participants, summary data for
each intervention group and subgroup analyses.
• Miscellaneous: funding, study author conflicts of interest, com-
ments, correspondence required.
We will resolve disagreements via discussion or with a third review
author as necessary. Where necessary, we will contact study inves-
tigators for clarification. We will extract adjusted or unadjusted re-
sults as guided by the Cochrane Handbook for Systematic Reviews
of Interventions (Handbook 2011).
Assessment of risk of bias in included studies
Two review authors will undertake assessment of the risk of bias
of the included trials independently, with the following taken in-
to consideration, as guided by theCochrane Handbook (Handbook
2011):
• sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We will use the Cochrane 'Risk of bias' tool in RevMan 5.3 (RevMan
2014), which involves describing each of these domains as report-
ed in the trial and then assigning a judgement about the adequacy
of each entry: 'low', 'high' or 'unclear' risk of bias. We will resolve
disagreements via discussion, or with a third review author as nec-
essary.
We will account for baseline imbalances between groups when as-
sessing selection bias according to the framework proposed by Cor-
bett 2014.
We will assess performance bias, detection bias and attrition bias
for each of the review outcomes separately. We will report and
group results as appropriate (for instance, by grouping self-report-
ed and objective outcomes separately). We will summarise an over-
all risk of bias per outcome (Higgins 2011; Appendix 2).
We will assess risk of bias associated with the reliability of outcome
measurement tools separately ('other bias' in the 'Risk of bias' tool)
and account for this in the interpretation of the results.
Measures of treatment e8ect
We will express dichotomous data as a risk ratio (RR) with 95% con-
fidence interval (CI). We will express continuous data (final values
will be preferred over change scores) as a standardised mean differ-
ence (SMD) with 95% CI. If studies perform an ANCOVA analysis to
account for a significant imbalance in outcome at baseline, then we
will use these results. Where possible we will express time-to-event
data (e.g. disease recurrence and re-treatment) as a hazard ratio.
We will calculate unadjusted treatment effects using Cochrane's
Review Manager (RevMan) software where possible (RevMan 2014).
Unit of analysis issues
We will take into account the level at which randomisation oc-
curred. Unit of analysis issues may arise where the unit of randomi-
sation differs from the unit of analysis. Trials may randomise par-
ticipants to the interventions but report outcomes on a per-ear ba-
sis. Where the number of ears appears to equal the number of par-
ticipants we will treat the ear as the unit of analysis. When this is not
the case we will contact the study authors and request additional
information to enable us to carry out a per-ear analysis, which takes
into account the fact that some of the data may be non-indepen-
dent. Pairing of data (within-patient) may arise where ears are both
randomised and analysed. For such studies we will prefer adjust-
ed results to account for within-person correlation and we will re-
quest additional information to enable us to calculate adjusted re-
sults from the study authors.
Dealing with missing data
Where necessary, we will contact the corresponding authors of in-
cluded studies to supply any unreported data (such as group means
and standard deviations (SDs), details of dropouts and details of in-
terventions received by the control group). If a study reports out-
comes only for participants completing the study or only for par-
ticipants who followed the protocol, we will contact the authors
and ask them to provide additional information to allow analyses
according to intention-to-treat principles. We will describe missing
data and dropouts/attrition for each included study in the 'Risk of
bias' tables, and discuss the extent to which the missing data may
affect the results and conclusions of the review. If data are still un-
available after author contact, we will use an available case analy-
sis method, where data are included on only those whose results
are known, using as a denominator the total number of people who
had data recorded for the particular outcome in question. We will
assess variation in the degree of missing data across studies as a
potential source of heterogeneity.
We will assess the sensitivity of any primary meta-analyses to miss-
ing data using the method recommended by Higgins et al (Higgins
2008). We will report missing data per group.
Assessment of heterogeneity
We will assess clinical variation across studies by comparing the
distribution of potentially important participant factors among tri-
als (e.g. baseline severity, co-morbidities), and trial factors (ran-
domisation concealment, blinding of outcome assessment, losses
to follow-up, BET balloon size, inflation pressure, device type).
We will visually inspect the forest plots for heterogeneity by looking
at the consistency of intervention effects across included studies.
Where possible, we will describe statistical heterogeneity by com-
puting the I2 statistic and Chi2 test. We will interpret the I2 and Chi2
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values following the guidance in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Handbook 2011).
Assessment of reporting biases
If sufficient studies are found, we will assess reporting biases by vi-
sual inspection of funnel plots. Where possible, as a direct test for
publication bias, we will compare results extracted from published
journal reports with results obtained from other sources.
Data synthesis
Where appropriate, we will carry out all the analyses on an inten-
tion-to-treat basis. We will use RevMan 5.3 to carry out the meta-
analyses for comparable trials and outcomes (RevMan 2014). We
will perform statistical analyses according to the statistical guide-
lines referenced in the most recent version of the Cochrane Hand-
book for Systematic Reviews of Interventions (Handbook 2011). In
the event of substantial clinical heterogeneity (for instance, signif-
icantly different presentations of Eustachian tube dysfunction) or
methodological or statistical heterogeneity, we will not pool stud-
ies in a meta-analysis and we will present the results in a narrative
summary. We will not pool split-person and between-person stud-
ies.
For some outcomes, such as Eustachian tube function test scores,
symptoms scores and quality of life measures, different scales may
be used, and some may be inverse to others. Where needed, we
will standardise scales through multiplication or inversion, to allow
comparison of results between methods.
We will look at all available data and, if data permit, combine and
stratify studies according to intervention characteristics (for exam-
ple, first- and second-line interventions, device and inflation char-
acteristics). For continuous outcomes, we will prefer change scores
over final values.
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analysis based on:
• the different presentations of Eustachian tube dysfunction;
• the use of a planned co-intervention.
Presentation of Eustachian tube dysfunction can vary from symp-
toms of pressure to visible manifestations of chronic otitis media
such as otitis media with effusion or cholesteatoma. We anticipate
that study authors may select groups of patients with the same pre-
sentation in order to measure the effects of BET in an homogenous
group.
If BET is used in combination with another intervention, for ex-
ample, grommet insertion (and compared with grommet inser-
tion alone) then that would also necessitate a subgroup analysis
(measuring the effect of BET as an adjunct to grommet insertion).
Large numbers of subgroup analyses may lead to misleading con-
clusions (Oxman 1992; Yusuf 1991), therefore these analyses will be
exploratory and we will treat any conclusions with caution. Where
possible we will investigate differences between two or more sub-
groups using the method described by Borenstein et al (Borenstein
2008).
Sensitivity analysis
We will perform sensitivity analysis to explore the influence of in-
cluding only studies with an overall low risk of bias per outcome
across all domains.
GRADE and 'Summary of findings' table
Two review authors (AP and MS) will independently use the GRADE
approach to rate the overall certainty of evidence for each outcome
using the GDT tool (http://www.guidelinedevelopment.org/).
The certainty of evidence reflects the extent to which we are confi-
dent that an estimate of effect is correct and we will apply this in
the interpretation of results. There are four possible ratings: high,
moderate, low and very low. A rating of high certainty of evidence
implies that we are confident in our estimate of effect and that fur-
ther research is very unlikely to change our confidence in the esti-
mate of effect. A rating of very low certainty implies that any esti-
mate of effect obtained is very uncertain.
The GRADE approach rates evidence from RCTs that do not have
serious limitations as high certainty. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
We will include a 'Summary of findings' table for the main compar-
isons listed (variations of 'BET versus conservative management').
This will be constructed according to the recommendations de-
scribed in Chapters 10 and 11 of theCochrane Handbook for System-
atic Reviews of Interventions (Handbook 2011). Other comparisons,
such as 'BET versus grommet insertion' will be tabulated separate-
ly. We will include the following primary outcomes:
• severity of patient-reported obstructive Eustachian tube dys-
function symptoms;
• Eustachian tube function measured by an objective or semi-ob-
jective test;
• adverse events (early and late).
Where possible, we will provide both relative and absolute mea-
sures of effect.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
1 MESH DESCRIPTOR Eustachian Tube EXPLODE ALL AND CENTRAL:TARGET
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2 ((eustachian or auditory or pharyngotympanic) next tube*):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET
3 (eustachian next (dysfunction OR canal or orifice*)):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET0
4 (middle next ear adj3 dysfunction*):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET
5 #1 OR #2 OR #3 OR #4 AND CENTRAL:TARGET
6 (balloon* and (dilation or dilated or Dilatation or catheter* or transtympanic or tubuloplast* or tuboplast*)):AB,EH,KW,KY,MC,MH,TI,TO
AND CENTRAL:TARGET
7 ((eustachian or endonasal or transtympanic or (middle next ear)) and (dilation or dilated or Dilatation or tubuloplast* or catheter* or
tuboplast*)):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET
8 EET or BDET or Bielefeld or AERA or BET or tubavent or XprESS or jarit or miltex or ETBD or integra AND CENTRAL:TARGET
9 MESH DESCRIPTOR Dilatation EXPLODE ALL AND CENTRAL:TARGET
10 MESH DESCRIPTOR Catheterization AND CENTRAL:TARGET
11 #6 OR #7 OR #8 OR #9 OR #10 AND CENTRAL:TARGET
12 #5 AND #11 AND CENTRAL:TARGET
13 MESH DESCRIPTOR Eustachian Tube EXPLODE ALL WITH QUALIFIER SU AND CENTRAL:TARGET
14 #12 OR #13 AND CENTRAL:TARGET
Appendix 2. Assessment of risk of bias
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random-number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule based
on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process provided to permit a judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method,
was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation); sequential-
ly-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as alloca-
tion based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without ap-
propriate safeguards (e.g. if envelopes were unsealed or non opaque or not sequentially-numbered); alternation or rotation; date of birth;
case record number; any other explicitly unconcealed procedure.
Unclear
Insufficient information provided to permit a judgement of low or high risk of bias. This is usually the case if the method of concealment
is not described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is
described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following.
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of
blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
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• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others
was unlikely to introduce bias.
High risk of bias
Any one of the following.
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken and the outcome or
outcome measurement is likely to be influenced by lack of blinding.
• Either participants or some key study personnel were not blinded, and the non-blinding was likely to introduce bias.
Unclear
Either of the following.
• Insufficient information provided to permit a judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following.
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was not enough to have a
clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes
was not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following.
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data
across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was enough to induce clini-
cally relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes
was enough to induce clinically relevant bias in observed effect size.
• ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Either of the following.
• Insufficient reporting of attrition/exclusions to permit a judgement of low or high risk of bias (e.g. number randomised not stated, no
reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following.
• The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the review
have been reported in the pre-specified way.
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• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following.
• Not all of the study’s pre-specified primary outcomes have been reported.
• One or more primary outcomes are reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were
not pre-specified.
• One or more reported primary outcomes of the study were not pre-specified (unless clear justification for their reporting is provided,
such as an unexpected adverse effect).
• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information provided to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this
category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important additional risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• has been claimed to have been fraudulent; or
• used non-or poorly validated outcome measures; or
• had significant baseline imbalances present for important prognostic variable(s) and had randomisation and/or allocation conceal-
ment methods that were inadequate or unclear, or had no baseline details and had randomisation and/or allocation concealment
methods that were inadequate (Corbett 2014);
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
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